Execution of Letter of Intent with Telexcell Trade PTE LTD, Singapore for Strategic Equity Investment

Listed-company acquisitionStrategic Transactions View source PDF Explain this filing

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+5.0%Reaction day

₹0.80

prior close

₹0.83

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used+1.0%+4.0% vs market

Pharmaceuticals peers, median of 150sector+0.7%+4.3% vs sector

On the reaction day the stock moved 4.0 pts more than Nifty Microcap 250 and 4.3 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.0

10m

+0.0

15m

+0.0

30m

+1.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+5.0+1.0+4.0+0.7+4.3

Next day

+7.5+0.3+7.2+0.2+7.3

+11.3+0.3+10.9+0.4+10.9

+13.8+0.8+13.0+0.5+13.3

+16.3+0.9+15.3+0.6+15.7

+11.3+1.4+9.9+0.6+10.6

+0.0+1.2-1.2+0.8-0.8

15d

-23.8+1.8-25.6+1.0-24.8

-31.3+0.1-31.3-1.1-30.1

-33.8+2.4-36.1-1.1-32.6

-31.3-2.8-28.4-5.5-25.7

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 150Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Welcure Drugs & Pharmaceuticals has executed a non-binding Letter of Intent with Singapore-based Telexcell Trade PTE LTD, which intends to acquire up to 25% equity stake in the company. The indicative price is ₹20 per share, representing a significant premium over the current market price of below ₹10. The transaction will be fully in cash and aims to strengthen Welcure's global footprint in pharmaceutical and chemical exports across emerging markets. The deal is subject to due diligence, execution of definitive agreements, and regulatory approvals from SEBI, RBI, and stock exchanges, with a 90-day window to complete these steps. The LOI is non-binding except for confidentiality and governing law provisions.

Likely market impact

Positive for shareholders as the proposed investment price of ₹20 per share is more than double the prevailing market price, signaling strong valuation validation. However, the deal remains non-binding and conditional, so investors should wait for the definitive agreement and regulatory clearances before drawing firm conclusions.